Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
NCT00673920Phase 3Terminated
- Sponsor
- Genentech
- Start
- Apr 2008
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in rheumatoid arthritis (RA) (8 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at 24 weeks. Started Apr 2008; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00673920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673920.